Seroepidemiological characteristics of hepatitis B virus among hospitalized patients aged 18 years or below in Henan Province of China

Wei LI; Yanhong KANG; Jiangfeng ZHANG; Hui YIN; Junping LIU; Yukui LI; Yi KANG

doi:10.3969/j.issn.1001-5256.2023.05.009

Volume 39 Issue 5

May 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(5): 1056-1060

PDF( 2003 KB)

Seroepidemiological characteristics of hepatitis B virus among hospitalized patients aged 18 years or below in Henan Province of China

DOI: 10.3969/j.issn.1001-5256.2023.05.009

a.
Department of Infectious Diseases, Henan Provincial People's Hospital, Zhengzhou 450003, China
b.
Department of Clinical Laboratory, Henan Provincial People's Hospital, Zhengzhou 450003, China

Research funding:

Henan Medical Science and Technology Research Program (LHGJ20190609);

Henan Natural Science Foundation Project (162300410294)

More Information

Corresponding author: KANG Yi, wwhhslek@126.com (ORCID: 0000-0002-4150-5270)
Received Date: 2023-01-27
Accepted Date: 2023-02-28
Published Date: 2023-05-20

Abstract

Abstract

Objective To investigate the current status of hepatitis B virus (HBV) infection among hospitalized patients aged 1-18 years, as well as the status of immunity after hepatitis B vaccination. Methods Related data were collected from the patients aged 1-18 years who were hospitalized in Henan Provincial People's Hospital from July 2020 to July 2021, including serological markers for hepatitis B (HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc) and hepatitis B vaccination. The epidemiological situation of HBV infection was analyzed, as well as the immune effect after vaccination. The trend chi-square test was used for trend analysis. Results A total of 10 658 hospitalized patients were collected, among whom there were 6 372 male patients (59.79%) and 4 286 female patients (40.21%). In this population, the patients with positive HBsAg accounted for 0.28% (30/10 658), with a relatively high proportion of 0.68% and 0.62%, respectively, in the 17-and 18-year age groups; the patients with positive anti-HBs accounted for 51.82% (5 523/10 658), with a relatively high proportion of > 63% in the 1-4 years age groups, and there was a reduction in the proportion of patients with positive anti-HBs (fluctuating around 40%) in the 5-18 years age groups. With the increase in age, the positive rate of anti-HBs tended to decrease in both male and female patients (male: χ²=8.217, P=0.004; female: χ²=10.048, P=0.002). Conclusion Based on the data of hospitalized patients, HBV infection in the population aged 1-18 years in Henan Province has the characteristics of low prevalence rate and high immunity, and the reduction in the proportion of patients with positive anti-HBs at more than five years after vaccination should be taken seriously in this region.
- Hepatitis B Virus,
- Biomarkers,
- Child

FullText(HTML)

References(10)

References

[1]	LIANG X, BI S, YANG W, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2009, 27(47): 6550-6557. DOI: 10.1016/j.vaccine.2009.08.048.
[2]	CUI F, SHEN L, LI L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23(5): 765-772. DOI: 10.3201/eid2305.161477.
[3]	Viral Hepatitis Group, Hepatology Branch of Chinese Research Hospital Association. Expert consensus on diagnosis and treatment of chronic hepatitis B virus with persistently normal alanine aminotransferase[J]. J Clin Hepatol, 2021, 37(10): 2286-2291. DOI: 10.3969/j.issn.1001-5256.2021.10.007. 中国研究型医院学会肝病学分会病毒性肝炎学组. ALT持续正常的慢性HBV感染者诊疗专家共识[J]. 临床肝胆病杂志, 2021, 37(10): 2286-2291. DOI: 10.3969/j.issn.1001-5256.2021.10.007.
[4]	DONG PM, LI J, GUO WS, et al. Seroepidemiolocal survey of hepatitis B virus infection among people aged 1-74 in Henan province[J]. Progress in Microbiology and Immunology, 2021, 49(1): 53-59. DOI: 10.13309/j.cnki.pmi.2021.01.009. 董蒲梅, 李军, 郭万申, 等. 河南省1~74岁人群乙型病毒性肝炎血清流行病学调查[J]. 微生物学免疫学进展, 2021, 49(1): 53-59. DOI: 10.13309/j.cnki.pmi.2021.01.009.
[5]	Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Management algorithm for interrupting mother-to-child transmission of hepatitis B virus(2021)[J]. J Clin Hepatol, 2021, 37(3): 527-531. DOI: 10.3969/j.issn.1001-5256.2021.03.007. 中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会. 阻断乙型肝炎病毒母婴传播临床管理流程(2021年)[J]. 临床肝胆病杂志, 2021, 37(3): 527-531. DOI: 10.3969/j.issn.1001-5256.2021.03.007.
[6]	Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association; Chinese Society of Perinatal Medicine, Chinese Medical Association. 2020 clinical guidelines on prevention of mother-to-child transmission of hepatitis B virus[J]. J Clin Hepatol, 2020, 36(7): 1474-1481. DOI: 10.3760/cma.j.cn112141-20200213-00101 中华医学会妇产科学分会产科学组, 中华医学会围产医学分会. 乙型肝炎病毒母婴传播预防临床指南(2020)[J]. 临床肝胆病杂志, 2020, 36(7): 1474-1481. DOI: 10.3760/cma.j.cn112141-20200213-00101
[7]	JING W, LIU J, LIU M. Eliminating mother-to-child transmission of HBV: progress and challenges in China[J]. Front Med, 2020, 14(1): 21-29. DOI: 10.1007/s11684-020-0744-2.
[8]	CHEN HP, ZHOU AM, WANG RY, et al. Seroepidemiological analysis of characteristic of hepatitis B virus in children after vaccination in Ningbo[J]. Chin J Epidemiol, 2001, 22(3): 184-187. DOI: 10.3760/j.issn:0254-6450.2001.03.009. 陈衡平, 周爱明, 王仁元, 等. 宁波市实施乙型肝炎疫苗计划免疫后儿童乙型肝炎病毒血清流行病学研究[J]. 中华流行病学杂志, 2001, 22(3): 184-187. DOI: 10.3760/j.issn:0254-6450.2001.03.009.
[9]	BAO C, CHEN DL, WANG XH, et al. Surveillance on effectiveness of hepatitis B virus vaccination in children and discussion on the earliest boosting age[J]. Prac Prev Med, 2017, 24(4): 394-396. DOI: 10.3969/j.issn.1006-3110.2017.04.004. 鲍春, 陈德黎, 王秀华, 等. 儿童乙型肝炎病毒疫苗免疫效果监测及强化免疫最小年龄探讨[J]. 实用预防医学, 2017, 24(4): 394-396. DOI: 10.3969/j.issn.1006-3110.2017.04.004.
[10]	CAO XZ, YI W, LIU XM, et al. The immune response and influencing factor of hepatitis B virus vaccine on 3-year-old children born to mothers infected with HBV[J/CD]. Chin J Liver Dis (Electronic Version), 2022, 14(2): 57-62. DOI: 10.3969/j.issn.1674-7380.2022.02.009.